Residual risk management educational programs

Showing 4 of 26

Lipid/Metabolic

Experts' Corner: HDL & Cardiovascular Risk — The Year in Review

Feb 3, 2012 10:01 EST

Join Drs Rader and Blumenthal as they discuss the results of this year's major trials looking at reducing cardiovascular risk and raising HDL-C.

Lipid/Metabolic

ACS in Patients with Type 2 Diabetes: Exploring New Pathways to Reduce Cardiovascular Risk

Jan 31, 2012 11:00 EST

Join Dr Jorge Plutzky as he discusses the potential for PPAR agonists in reducing cardiovascular risk in patients with type 2 diabetes.

Lipid/Metabolic

Is CETP Inhibition the Answer to Residual Risk? A Global Perspective

Jan 24, 2012 14:22 EST

Join Drs. Rosenson, Lüscher, and Deanfield as they discuss the potential clinical impact of AIM-HIGH and the latest CETP-inhibitor clinical trials from a global perspective.

Lipid/Metabolic

Addressing Residual Risk in the ACS Patient: Knowing the Numbers

Dec 21, 2011 08:21 EST

Join Drs. Chapman, Gotto, and Kastelein as they discuss the results of AIM-HIGH and the latest CETP-inhibitor clinical trials in HDL-targeted residual cardiovascular risk reduction.

Lipid/Metabolic

AIM-HIGH and the HDL Paradigm in Focus

2 COMMENTS - Dec 12, 2011 09:00 EST

This survey aims to gauge your perception of the recently published AIM-HIGH trial, and physician practice patterns in the management of patients with dyslipidemia and low HDL-C.

Lipid/Metabolic

HDL-C and AIM-HIGH: Does Increasing HDL-C Reduce Cardiovascular Risk?

Dec 9, 2011 14:12 EST

Join Drs. Davidson, Toth, and Boden as they discuss the results of the AIM-HIGH trial and its implications on the treatment of low HDL-C with currently available agents.

Lipid/Metabolic

HDL and CHD: New Mechanisms Targeting Risk

1 COMMENT - Dec 7, 2011 10:15 EST

Join Drs. Eckel, Ridker, and Cannon for a panel discussion on the relationship among LDL-C, low HDL-C, and therapies in development targeting residual CV risk.

Lipid/Metabolic

Dilemmas in Diabetes and Cardiovascular Disease: Positioning PPAR Agonists to Address the Big Picture

Nov 17, 2011 15:00 EST

Join Drs. Betteridge and Charbonnel as they discuss PPAR agonists in development and their potential in cardiovascular risk reduction.

Lipid/Metabolic

HDL: The Next Frontier in Reducing Atherosclerosis and Cardiovascular Risk in Type 2 Diabetes?

2 COMMENTS - Nov 1, 2011 09:00 EDT

Join Drs. Bruckert, von Eckardstein, and Stalenhoef as they discuss the latest data on reducing residual cardiovascular risk in patients with type 2 diabetes.

Lipid/Metabolic

Residual Risk Management and HDL: Clinician Survey

2 COMMENTS - Oct 21, 2011 09:30 EDT

There is growing evidence that targeting HDL may reduce residual CV risk. You are invited to participate in this educational survey to gauge physician practice patterns and knowledge of dyslipidemia.

Lipid/Metabolic

HDL Targeting Therapies: Updates from the European Society of Cardiology

Sep 28, 2011 12:00 EDT

Join Drs. Barter, Fayad, Kastelein, and Nicholls as they discuss HDL functionality and the clinical implications of HDL modulation.

Lipid/Metabolic

Can Targeting CETP Halt Atherosclerosis Progression? Examining the Evidence

8 COMMENTS - Sep 28, 2011 09:00 EDT

Join Drs. Tardif and Fayad for a discussion of the latest clinical trials in HDL-C-modifying therapy.

Lipid/Metabolic

HDL-C in the Spotlight: Modulating CETP to Reduce Cardiovascular Risk

Sep 19, 2011 09:17 EDT

Join Drs. Chapman, Brewer, and Deanfield for a discussion on low HDL-C and the potential role CETP inhibitors may play in reducing residual cardiovascular risk.

Lipid/Metabolic

Residual Cardiovascular Risk Management: HDL-C in Focus

34 COMMENTS - Sep 6, 2011 11:03 EDT

This survey is being conducted to gauge physician-practice patterns in the management of patients with dyslipidemia and low HDL-C.

Lipid/Metabolic

First Response from the European Society of Cardiology (ESC): Emerging Therapies Targeting HDL

Sep 1, 2011 10:23 EDT

Interpret emerging clinical data concerning the safety and clinical implications of cholesteryl ester transfer protein inhibition and the future implications of trials on HDL modulation in reduction of cardiovascular risk.

Lipid/Metabolic

Novel, Targeted, and Appropriate PPAR Therapy: New Paradigms for Residual Risk Management

1 COMMENT - Aug 26, 2011 11:23 EDT

What do clinical trials tell us about the use of PPARs for residual risk management in type 2 diabetes and cardiovascular disease?

Lipid/Metabolic

Residual Risk Management: Case-Based Assessment

4 COMMENTS - Aug 22, 2011 16:00 EDT

Despite receiving LDL-C-lowering therapy, residual cardiovascular risk remains significant in patients with dyslipidemia. You are invited to participate in this educational survey to gauge physician-practice patterns in the management of dyslipidemia.

Lipid/Metabolic

HDL and the Dyslipidemia of Diabetes: Examining the Increased Risk of Atherosclerotic Events in Type 2 Diabetes

Aug 17, 2011 09:59 EDT

Address the lipid abnormalities and how to understand them from a clinically practical point of view, and evaluate how lifestyle changes and appropriate medication can improve HDL levels and attenuate cardiovascular risk in these patients.

Lipid/Metabolic

Achieving HDL-C Goals in Patients With Type 2 Diabetes: Case-Based Discussions on the Therapeutic Challenges

1 COMMENT - Aug 2, 2011 09:00 EDT

Join Drs. Plutzky and Eckel for a case-based discussion on the treatment of low HDL-C in patients with type 2 diabetes.

Lipid/Metabolic

Spotlight on PPAR Therapy in Cardiovascular Disease

1 COMMENT - Jun 2, 2011 14:11 EDT

What are the molecular and cellular mechanisms targeted by PPAR therapy and what is their relevance in management of macrovascular and microvascular cardiovascular disease?

Lipid/Metabolic

Residual CVD Risk After Statin Treatment: Exploring the Promise and Opportunities of HDL Modulation

9 COMMENTS - Jun 2, 2011 14:10 EDT

What do clinical studies reveal about emerging treatment options and how they may decrease residual CV risk in patients with CVD?

Lipid/Metabolic

Current Perceptions on Residual Cardiovascular Risk Management

4 COMMENTS - Apr 29, 2011 14:00 EDT

Despite receiving guidelines-based therapy that focuses primarily on lowering LDL cholesterol, patients with dyslipidemia may have significant residual cardiovascular risk. There is extensive evidence that targeting other lipids, such as HDL cholesterol, may be just as important in reducing CV risk. This survey is being conducted to gauge physician practice patterns in the management of patients with dyslipidemia and low HDL-C.

Lipid/Metabolic

Evolution of CETP as a Target for Coronary Heart Disease Prevention

Apr 21, 2011 13:30 EDT

Join Dr. Packard as he discusses emerging strategies for HDL-C elevation in patients at risk for coronary heart disease.

Lipid/Metabolic

Spotlight on HDL Modulation in Residual Risk Management

6 COMMENTS - Dec 30, 2010 10:22 EST

Is there a safe way to raise HDL levels and lower the risk of cardiovascular disease?

Lipid/Metabolic

The Impact of HDL-C Elevation on Patient Outcomes: What Do the Data Tell Us?

Sep 7, 2010 13:26 EDT

In 2009, NLA members identified HDL-C management as one of their top 5 educational needs to be addressed. In this CME activity, Dr. Peter Toth reviews the latest advances for the management of HDL-C.

Lipid/Metabolic

Residual Risk Management Poll

8 COMMENTS - Apr 19, 2010 09:48 EDT

How would you treat this 55-year-old patient with diabetes? Answer this short polling question and learn your peers' responses.

Virtual Grand RoundsShowing 22 of 2

Lipid/Metabolic

Highlight on CETP: Role in Lipid Metabolism and Homeostasis

Dec 23, 2011 09:45 EST

Join Dr. Rader as he discusses whether a change in HDL cholesterol level reflects proper HDL particle function or therapeutic success.

Lipid/Metabolic

HDL Quality: Is It a Better Target Than HDL-C?

Dec 20, 2011 11:21 EST

Join Dr. Nicholls as he discusses the clinical significance of HDL-C for residual cardiovascular risk and whether HDL functionality would be a better predictor of therapeutic success. And DISCUSS this topic with Dr. Nicholls on Medscape Discuss.

CME provider: Medscape, LLC.

	Yes
	No